CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
暂无分享,去创建一个
S. Ekker | J. Mochel | A. Jergens | A. LeBlanc | K. Allenspach | Wesley A. Wierson | S. Benzekry | S. Kenderian | Agnes Bourgois-Mochel | Michael Knouse | Chad M Johannes
[1] Elisa A. Hurley,et al. The Next Phase of Human Gene-Therapy Oversight. , 2019, The New England journal of medicine.
[2] B. Powers,et al. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs , 2018, Journal of veterinary internal medicine.
[3] Jocelyn Kaiser,et al. Cancer immunotherapy sweeps Nobel for medicine. , 2018, Science.
[4] Carla M. Mann,et al. GeneWeld: a method for efficient targeted integration directed by short homology , 2018, bioRxiv.
[5] Delong Liu,et al. Cytokine release syndrome: grading, modeling, and new therapy , 2018, Journal of Hematology & Oncology.
[6] A. Ribas,et al. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL , 2018, Leukemia & lymphoma.
[7] James H. Doroshow,et al. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma , 2018, Clinical Cancer Research.
[8] Philip A. Kramer,et al. Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation , 2018, The Journal of experimental medicine.
[9] L. Deangelis,et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.
[10] M. Sadelain,et al. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.
[11] J. Maher,et al. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors , 2018, Front. Immunol..
[12] Hongming Zhu,et al. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review , 2018, Annals of Hematology.
[13] M. Ackermann,et al. Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease , 2018, Journal of veterinary internal medicine.
[14] P. Toutain,et al. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed‐effects to characterize and quantify variability in drug pharmacokinetics , 2018, Journal of veterinary pharmacology and therapeutics.
[15] M. Čemažar,et al. Antitumor effect of antibiotic resistance gene-free plasmids encoding interleukin-12 in canine melanoma model , 2018, Cancer Gene Therapy.
[16] A. Jimeno,et al. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas. , 2018, Drugs of today.
[17] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[18] Mithat Gonen,et al. Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[19] J. Tolar,et al. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T , 2018, International journal of molecular sciences.
[20] J. Mochel,et al. Model‐Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative , 2017, CPT: pharmacometrics & systems pharmacology.
[21] Value in Using CAR T Cells for DLBCL. , 2018, Cancer discovery.
[22] P. Hwu,et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.
[23] Stephen J. Schuster,et al. Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.
[24] A. Ashworth,et al. Reprogramming human T cell function and specificity with non-viral genome targeting , 2017, bioRxiv.
[25] M. Wurfel,et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.
[26] M. Ruella,et al. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf , 2017, BioDrugs.
[27] J. Cerhan,et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.
[28] R. Brentjens,et al. Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, Pharmacology & therapeutics.
[29] G. Morgan,et al. Immunologic approaches for the treatment of multiple myeloma. , 2017, Cancer treatment reviews.
[30] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[31] Katy Rezvani,et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. , 2016, The Journal of clinical investigation.
[32] K. Axhausen,et al. Swiss Canine Cancer Registry 1955-2008: Occurrence of the Most Common Tumour Diagnoses and Influence of Age, Breed, Body Size, Sex and Neutering Status on Tumour Development. , 2016, Journal of comparative pathology.
[33] Daniel Li,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.
[34] M. Fink,et al. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. , 2016, Journal of veterinary pharmacology and therapeutics.
[35] G. Wertheim,et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.
[36] M. Linden,et al. The Comparative Diagnostic Features of Canine and Human Lymphoma , 2016, Veterinary sciences.
[37] J. Jacob. Researchers Turn to Canine Clinical Trials to Advance Cancer Therapies. , 2016, JAMA.
[38] Mark Dewhirst,et al. Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology , 2016, Science Translational Medicine.
[39] P. Morley,et al. Breed Distribution and Clinical Characteristics of B Cell Chronic Lymphocytic Leukemia in Dogs , 2016, Journal of veterinary internal medicine.
[40] S. Nass,et al. The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary , 2015 .
[41] C. Khanna,et al. Defining the Value of a Comparative Approach to Cancer Drug Development , 2015, Clinical Cancer Research.
[42] E. Blyth,et al. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. , 2015, Cytotherapy.
[43] Matthew Breen,et al. Comparative oncology: what dogs and other species can teach us about humans with cancer , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[44] M. Kiupel,et al. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma , 2015, PloS one.
[45] T. Nakagawa,et al. Gene Electrotransfer of Canine Interleukin 12 into Canine Melanoma Cell Lines , 2015, The Journal of Membrane Biology.
[46] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[48] M. Danhof,et al. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned? , 2015, Reviews of physiology, biochemistry and pharmacology.
[49] M. Danhof,et al. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs , 2015, Pharmaceutical Research.
[50] M. Kalos,et al. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. , 2014, Cancer research.
[51] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[52] J. Modiano,et al. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. , 2014, Veterinary immunology and immunopathology.
[53] K. Propert,et al. A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma , 2014, PloS one.
[54] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[55] K. Richards,et al. Man’s best friend: what can pet dogs teach us about non-Hodgkin lymphoma? , 2014 .
[56] C. Fan,et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. , 2013, Cancer research.
[57] P. Toutain,et al. Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology. , 2013, Journal of veterinary pharmacology and therapeutics.
[58] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[59] Stefano Comazzi,et al. The dog as a possible animal model for human non‐Hodgkin lymphoma: a review , 2013, Hematological oncology.
[60] K. Kreuzer,et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.
[61] J. Modiano,et al. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies , 2012, Leukemia & lymphoma.
[62] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[63] M. May,et al. NEMO-Binding Domain Peptide Inhibits Constitutive NF-κB Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma , 2011, Clinical Cancer Research.
[64] Hao Liu,et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.
[65] S. Rosenberg,et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.
[66] Jonathan M. Green,et al. An enigmatic tail of CD28 signaling. , 2010, Cold Spring Harbor perspectives in biology.
[67] D. Thamm,et al. The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual laboratory. , 2010, Veterinary journal.
[68] H. Heslop,et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.
[69] M. Sadelain,et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[70] M. Paoloni,et al. The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway , 2009, PLoS medicine.
[71] S. Hirschfeld,et al. Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer Patients , 2009, Clinical Cancer Research.
[72] R. Chun. Lymphoma: which chemotherapy protocol and why? , 2009, Topics in companion animal medicine.
[73] S. Libutti,et al. Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature , 2009, PloS one.
[74] I. Pastan,et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.
[75] Hao Liu,et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.
[76] Jinjuan Wang,et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.
[77] M. Paoloni,et al. Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.
[78] J. Modiano,et al. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionship , 2008, Chromosome Research.
[79] C. June,et al. 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.
[80] H. Dombret,et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.
[81] Rajesh Chopra,et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.
[82] Gang Wang,et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.
[83] K. McKeever,et al. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. , 2006, Veterinary journal.
[84] P. Quesenberry,et al. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. , 2006, Journal of veterinary internal medicine.
[85] S. Fosmire,et al. CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma , 2005, Veterinary pathology.
[86] H. Schneider,et al. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling , 2003, Nature Reviews Immunology.
[87] J. Wood,et al. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. , 2002, The Journal of small animal practice.
[88] Michael Karin,et al. NF-kappaB at the crossroads of life and death. , 2002, Nature immunology.
[89] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[90] J. Bluestone,et al. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. , 1996, Journal of immunology.
[91] E. Benjamini,et al. TUMOR VACCINES FOR IMMUNOTHERAPY OF CANINE LYMPHOSARCOMA * , 1976, Annals of the New York Academy of Sciences.
[92] R. Storb,et al. Treatment of canine malignancies by 1200 R total body irradiation and autologous marrow grafts. , 1975, Experimental hematology.
[93] R. Storb,et al. Lymphocyte reactivity to autochthonous tumor cells in dogs with spontaneous malignancies. , 1974, Cellular immunology.